Invesco Ltd. Humanigen, Inc Transaction History

Invesco Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $33,496 - $63,376	-19,032 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $264 - $579	-146 Reduced 0.76%	19,032 $57,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $735 - $1,652	201 Added 1.06%	19,178 $71,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $23,862 - $71,747	4,024 Added 26.91%	18,977 $113,000
Q2 2021 Aug 17, 2021	BUY	$13.54 - $22.74 $202,463 - $340,031	14,953 New	14,953 $260,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.